TriangleNCT02663518 · OUTCOME
Part 4: Duration of Response (DoR)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From first dose of study till the progressive disease/death or withdrawal (maximum observation 6 years 10 months)
What was measured
DoR was defined, in participants who achieved a response as time from the first date of response to the first date of recurrent or progression disease. Participants without recurrent or progression disease were censored on date of the last adequate disease assessment, date of initiation of anticancer treatment or death of death, whichever was the earliest.
Analysis population: Analysis population included all the participants who received at least one dose of study treatment. Here, "Number of Participants Analyzed" refers to participants evaluable for this outcome measure.
Groups in this outcome
Part 4: Ontorpacept (PF-07901800/TTI-621) 0.5 mg/kg
Participants with relapsed or refractory CTCL received TTI-621 0.5 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
Part 4: Ontorpacept (PF-07901800/TTI-621) 0.7 mg/kg
Participants with relapsed or refractory CTCL received TTI-621 0.7 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
Part 4: Ontorpacept (PF-07901800/TTI-621) 1.0 mg/kg
Participants with relapsed or refractory CTCL received TTI-621 1.0 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
Part 4: Ontorpacept (PF-07901800/TTI-621) 1.4 mg/kg
Participants with relapsed or refractory CTCL received TTI-621 1.4 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
Part 4: Ontorpacept (PF-07901800/TTI-621) 2.0 mg/kg
Participants with relapsed or refractory CTCL received TTI-621 2.0 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
Part 4: Ontorpacept (PF-07901800/TTI-621) Q2W / 2.0 mg/kg
Participants with relapsed or refractory CTCL received a 2.0 mg/kg TTI-621 infusion once every 2 weeks until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
| Group | Source count |
|---|---|
| Part 4: Ontorpacept (PF-07901800/TTI-621) 0.5 mg/kg | 0 |
| Part 4: Ontorpacept (PF-07901800/TTI-621) 0.7 mg/kg | 0 |
| Part 4: Ontorpacept (PF-07901800/TTI-621) 1.0 mg/kg | 1 |
| Part 4: Ontorpacept (PF-07901800/TTI-621) 1.4 mg/kg | 1 |
| Part 4: Ontorpacept (PF-07901800/TTI-621) 2.0 mg/kg | 2 |
| Part 4: Ontorpacept (PF-07901800/TTI-621) Q2W / 2.0 mg/kg | 0 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 4: Ontorpacept (PF-07901800/TTI-621) 1.0 mg/kg | NA | Not reported | NA | NA | Median and 95% CI could not be estimated due to less number of participants with events. |
| Part 4: Ontorpacept (PF-07901800/TTI-621) 1.4 mg/kg | NA | Not reported | NA | NA | Median and 95% CI could not be estimated due to less number of participants with events. |
| Part 4: Ontorpacept (PF-07901800/TTI-621) 2.0 mg/kg | NA | Not reported | NA | NA | Median and 95% CI could not be estimated due to less number of participants with events. |
Complete source fields
- classes
- categories
- measurements
- comment
- Median and 95% CI could not be estimated due to less number of participants with events.
- group Id
- OG002
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- Median and 95% CI could not be estimated due to less number of participants with events.
- group Id
- OG003
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- Median and 95% CI could not be estimated due to less number of participants with events.
- group Id
- OG004
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 1
- group Id
- OG004
- value
- 2
- group Id
- OG005
- value
- 0
- units
- Participants
- description
- DoR was defined, in participants who achieved a response as time from the first date of response to the first date of recurrent or progression disease. Participants without recurrent or progression disease were censored on date of the last adequate disease assessment, date of initiation of anticancer treatment or death of death, whichever was the earliest.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants with relapsed or refractory CTCL received TTI-621 0.5 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- OG000
- title
- Part 4: Ontorpacept (PF-07901800/TTI-621) 0.5 mg/kg
- description
- Participants with relapsed or refractory CTCL received TTI-621 0.7 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- OG001
- title
- Part 4: Ontorpacept (PF-07901800/TTI-621) 0.7 mg/kg
- description
- Participants with relapsed or refractory CTCL received TTI-621 1.0 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- OG002
- title
- Part 4: Ontorpacept (PF-07901800/TTI-621) 1.0 mg/kg
- description
- Participants with relapsed or refractory CTCL received TTI-621 1.4 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- OG003
- title
- Part 4: Ontorpacept (PF-07901800/TTI-621) 1.4 mg/kg
- description
- Participants with relapsed or refractory CTCL received TTI-621 2.0 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- OG004
- title
- Part 4: Ontorpacept (PF-07901800/TTI-621) 2.0 mg/kg
- description
- Participants with relapsed or refractory CTCL received a 2.0 mg/kg TTI-621 infusion once every 2 weeks until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- OG005
- title
- Part 4: Ontorpacept (PF-07901800/TTI-621) Q2W / 2.0 mg/kg
- param Type
- MEDIAN
- population Description
- Analysis population included all the participants who received at least one dose of study treatment. Here, "Number of Participants Analyzed" refers to participants evaluable for this outcome measure.
- reporting Status
- POSTED
- time Frame
- From first dose of study till the progressive disease/death or withdrawal (maximum observation 6 years 10 months)
- title
- Part 4: Duration of Response (DoR)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice